[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2021014113A - Derivados de aminoquinazolina como inhibidores del purinoreceptor 3 de p2x (p2x3). - Google Patents

Derivados de aminoquinazolina como inhibidores del purinoreceptor 3 de p2x (p2x3).

Info

Publication number
MX2021014113A
MX2021014113A MX2021014113A MX2021014113A MX2021014113A MX 2021014113 A MX2021014113 A MX 2021014113A MX 2021014113 A MX2021014113 A MX 2021014113A MX 2021014113 A MX2021014113 A MX 2021014113A MX 2021014113 A MX2021014113 A MX 2021014113A
Authority
MX
Mexico
Prior art keywords
compounds
quinazoline derivatives
inhibitors
amino quinazoline
relates
Prior art date
Application number
MX2021014113A
Other languages
English (en)
Inventor
Matteo Biagetti
Paolo Ronchi
Claudio Fiorelli
Paolo Bruno
Charles Baker-Glenn
De Poël Hervè Van
Daniela Pizzirani
Daniele Pala
Kim Louise Hirst
Sara Guariento
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of MX2021014113A publication Critical patent/MX2021014113A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a compuestos de la fórmula I que inhiben el purinoceptor 3 de P2X; particularmente la invención se refiere a compuestos que son derivados de aminoquinazolina, métodos para preparar estos compuestos, composiciones farmacéuticas que los contienen y uso terapéutico de los mismos. Los compuestos de la invención pueden ser útiles en el tratamiento de muchos trastornos asociados con mecanismos de receptores P2X3, tal como enfermedades respiratorias que incluyen tos, asma, fibrosis pulmonar idiopática (FPI) y enfermedad pulmonar obstructiva crónica (EPOC).
MX2021014113A 2019-05-31 2020-05-28 Derivados de aminoquinazolina como inhibidores del purinoreceptor 3 de p2x (p2x3). MX2021014113A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19177604 2019-05-31
EP19201168 2019-10-02
PCT/EP2020/064914 WO2020239952A1 (en) 2019-05-31 2020-05-28 Amino quinazoline derivatives as p2x3 inhibitors

Publications (1)

Publication Number Publication Date
MX2021014113A true MX2021014113A (es) 2021-12-10

Family

ID=70861506

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021014113A MX2021014113A (es) 2019-05-31 2020-05-28 Derivados de aminoquinazolina como inhibidores del purinoreceptor 3 de p2x (p2x3).
MX2021014115A MX2021014115A (es) 2019-05-31 2020-05-28 Derivados de aminoquinazolina como inhibidores del purinoreceptor 3 de p2x (p2x3).

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021014115A MX2021014115A (es) 2019-05-31 2020-05-28 Derivados de aminoquinazolina como inhibidores del purinoreceptor 3 de p2x (p2x3).

Country Status (17)

Country Link
US (2) US20220227749A1 (es)
EP (2) EP3976179A1 (es)
JP (2) JP2022534303A (es)
KR (2) KR20220016498A (es)
CN (3) CN113891745B (es)
AU (2) AU2020285336A1 (es)
BR (2) BR112021022099A2 (es)
CA (2) CA3139019A1 (es)
CL (1) CL2021003165A1 (es)
CO (1) CO2021017031A2 (es)
IL (1) IL288405A (es)
MA (2) MA56021A (es)
MX (2) MX2021014113A (es)
PE (1) PE20220934A1 (es)
SG (1) SG11202112187YA (es)
WO (2) WO2020239951A1 (es)
ZA (1) ZA202108273B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11458149B1 (en) 2019-05-31 2022-10-04 Ikena Oncology, Inc. TEAD inhibitors and uses thereof
KR20220027871A (ko) 2019-05-31 2022-03-08 얀센 파마슈티카 엔.브이. NF-kB 유도 키나아제의 소분자 억제제
WO2022063205A1 (zh) * 2020-09-24 2022-03-31 中国医药研究开发中心有限公司 芳基甲酰胺类化合物及其制备方法和医药用途
JP2023550830A (ja) * 2020-11-27 2023-12-05 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ Ｐ２ｘ３阻害剤としての（アザ）キノリン４－アミン誘導体
AU2021388923A1 (en) * 2020-11-27 2023-05-25 Chiesi Farmaceutici S.P.A. Amino quinazoline derivatives as p2x3 inhibitors
CN112661803A (zh) * 2020-12-17 2021-04-16 上海药明康德新药开发有限公司 DNA编码化合物库构建中On-DNA 4-胺基喹唑啉化合物的合成方法
EP4267554A1 (en) * 2020-12-22 2023-11-01 Mekanistic Therapeutics LLC Substituted aminobenzyl heteroaryl compounds as egfr and/or pi3k inhibitors
CN114907284B (zh) * 2021-02-10 2023-11-03 石药集团中奇制药技术（石家庄）有限公司 一种具有抗肿瘤活性的化合物及其用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH31122A (en) * 1993-03-31 1998-02-23 Eisai Co Ltd Nitrogen-containing fused-heterocycle compounds.
EP2343282B1 (en) * 2004-03-05 2015-07-22 F. Hoffmann-La Roche AG Diaminopyrimidines as P2X3 and P2X2/3 antagonists
ATE537169T1 (de) * 2005-08-15 2011-12-15 Hoffmann La Roche Piperidin- und piperazinderivate als p2x3- antagonisten
CN103159692B (zh) 2006-06-29 2015-03-18 弗·哈夫曼-拉罗切有限公司 四唑取代的芳基酰胺类
EP2136639B1 (en) 2007-04-02 2016-03-09 Evotec AG Pyrid-2-yl fused heterocyclic compounds, and compositions and uses thereof
EP2139334B1 (en) 2007-04-17 2013-07-03 Evotec AG 2-cyanophenyl fused heterocyclic compounds, and compositions and uses thereof
MX2010009561A (es) 2008-02-29 2010-09-24 Renovis Inc Compuestos amida, composiciones y usos de los mismos.
US20110237578A1 (en) 2008-09-18 2011-09-29 Zhi-Liang Wei Amide compounds, compositions and uses thereof
KR101685862B1 (ko) * 2012-12-27 2016-12-20 에프. 호프만-라 로슈 아게 Comt 억제제
EP3200797A1 (en) * 2014-09-30 2017-08-09 Bristol-Myers Squibb Company Quinazoline-based kinase inhibitors
JPWO2016084922A1 (ja) 2014-11-28 2017-09-07 塩野義製薬株式会社 １，２，４−トリアジン誘導体およびその医薬組成物
JPWO2016088838A1 (ja) 2014-12-04 2017-09-14 塩野義製薬株式会社 プリン誘導体およびその医薬組成物
BR112017012327B1 (pt) 2014-12-09 2023-04-11 Bayer Aktiengesellschaft Benzamidas substituídas por 1,3-tiazol-2-il, seus usos, e composição farmacêutica
WO2017011729A1 (en) 2015-07-16 2017-01-19 Patara Pharma, LLC Combination therapies for the treatment of lung diseases
JP6877441B2 (ja) 2015-09-29 2021-05-26 アファレント ファーマシューティカルズ インコーポレイテッド 咳の処置における使用のためのジアミノピリミジンｐ２ｘ３及びｐ２ｘ２／３受容体修飾因子
WO2017091661A1 (en) * 2015-11-25 2017-06-01 Strovel Jeffrey William Bicyclic bet bromodomain inhibitors and uses thereof
CA3029457A1 (en) * 2016-06-30 2018-01-04 Gilead Sciences, Inc. 4,6-diaminoquinazolines as cot modulators and methods of use thereof
US10898487B2 (en) * 2016-12-22 2021-01-26 Boehringer Ingelheim International Gmbh Benzylamino substituted quinazolines and derivatives as SOS1 inhibitors
EP3619193B1 (en) * 2017-05-05 2023-03-22 Hepanova, Inc. Amino-aryl-benzamide compounds and methods of use thereof

Also Published As

Publication number Publication date
KR20220016499A (ko) 2022-02-09
PE20220934A1 (es) 2022-05-31
JP2022534303A (ja) 2022-07-28
MX2021014115A (es) 2021-12-10
MA56022A (fr) 2022-04-06
CN118239931A (zh) 2024-06-25
CN113891745A (zh) 2022-01-04
IL288405A (en) 2022-01-01
CL2021003165A1 (es) 2022-09-23
CA3139019A1 (en) 2020-12-03
CO2021017031A2 (es) 2022-01-17
WO2020239951A1 (en) 2020-12-03
JP2022534751A (ja) 2022-08-03
US20230092892A1 (en) 2023-03-23
MA56021A (fr) 2022-04-06
CN114269432A (zh) 2022-04-01
AU2020285336A1 (en) 2022-01-06
BR112021021738A2 (pt) 2021-12-28
KR20220016498A (ko) 2022-02-09
SG11202112187YA (en) 2021-12-30
WO2020239952A1 (en) 2020-12-03
ZA202108273B (en) 2023-07-26
AU2020281923A1 (en) 2022-01-06
CN113891745B (zh) 2024-05-07
EP3976180A1 (en) 2022-04-06
CN114269432B (zh) 2024-05-07
US20220227749A1 (en) 2022-07-21
EP3976179A1 (en) 2022-04-06
CA3139018A1 (en) 2020-12-03
BR112021022099A2 (pt) 2021-12-28

Similar Documents

Publication Publication Date Title
MX2021014115A (es) Derivados de aminoquinazolina como inhibidores del purinoreceptor 3 de p2x (p2x3).
SA519402319B1 (ar) Rho- مشتقات أميد التيروسين كمثبطات لإنزيم الكيناز
MX2019005526A (es) Derivados biciclicos de dihidropirimidina-carboxamida como inhibidores de rho-cinasa.
MX2020012202A (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo para el tratamiento de enfermedades asociadas a la sensibilizacion de fibras nerviosas.
EA201691375A1 (ru) (2s)-n-[(1s)-1-циано-2-фенилэтил]-1,4-оксазепан-2-карбоксамиды в качестве ингибиторов дипептидилпептидазы i
MX2021000270A (es) Derivados de la tirosina amida como inhibidores de la rho- cinasa.
EA201590030A1 (ru) Ингаляторы сухого порошка, содержащие носитель, отличный от лактозы, и третий компонент
MX2018008439A (es) Orvepitant para el tratamiento de la tos cronica.
MX2022013014A (es) Nuevas formas cristalinas de trifenatato de vilanterol y procedimientos para su preparacion.
WO2016168553A8 (en) Deuterated obeticholic acid
EA201892818A1 (ru) Бета-шпилечные пептидомиметики, обладающие ингибирующей активностью в отношении эластазы, и содержащие их лекарственные формы в виде аэрозоля
MX2021014116A (es) Derivados de piridopirimidinas como inhibidores del purinoreceptor 3 de p2x (p2x3).
MX2023005801A (es) Derivados de ftalazina como inhibidores de purinoceptor 3 de p2x (p2x3).
MX2023005805A (es) Derivados de 4-aminas de (aza)quinolina como inhibidores del purinorreceptor 3 p2x (p2x3).
MX2023005803A (es) Derivados de amino-quinazolina como inhibidores del purinorreceptor 3 p2x (p2x3).
MX368036B (es) Particulas inhalables que comprenden tiotropio e indacaterol.
NO20081483L (no) Kombinasjon av forbindelser som kan brukes ved behandling av respiratoriske sykdommer, spesielt kronisk obstruktiv pulmonaer sykdom (COPD) og astma
EA202193300A1 (ru) Производные аминохиназолина в качестве p2x3 ингибиторов
MX2021015553A (es) Inhibidores de arginasa novedosos.
MX2023005867A (es) Derivados de dihidrofuropiridina como inhibidores de la cinasa rho.
MX2023005865A (es) Derivados de dihidrofuropiridina como inhibidores de rho-cinasa.
MX2023005866A (es) Derivados de dihidrofuropiridina como inhibidores de rho-cinasa.
MX2022004809A (es) Composiciones para prevenir o tratar enfermedad pulmonar obstructiva cronica (epoc).
NZ761390A (en) Boysenberry, apple, and blackcurrant compositions and methods of preparation and use therefor
TR201720845A1 (tr) Oral farmasöti̇k terki̇pler